Methylation profiling in multiple myeloma
- PMID: 15109538
- DOI: 10.1016/j.leukres.2003.08.008
Methylation profiling in multiple myeloma
Abstract
Background: We analysed the methylation status of a panel of 10 genes including p15, p16, DAPK, p73, VHL, E-CAD, MGMT, RARbeta, RIZ1, and ER.
Methods: The gene promoter methylation status was studied by methylation-specific polymerase chain reaction (MSP) with primers for methylated (M-MSP) and unmethylated (U-MSP) DNA in the bone marrow of 13 patients with myeloma, and one patient with plasmacytoma.
Result: None of the 10 genes tested were methylated in eight normal bone marrow samples. For the positive control, the sensitivity of M-MSP ranged from 1 x 10(-2) for E-CAD and MGMT, to 1 x 10(-4) for p73. Of the eight diagnostic myeloma marrow samples, hypermethylation of p15, p16, E-CAD, DAPK and ER occurred in six (75%), four (50%), seven (87.5%), eight (100%), and six (75%) patients. Similarly, of the five samples from patients who progressed from plateau phase, hypermethylation of p15, p16, E-CAD, DAPK, and ER occurred in five (80%), two (40%), five (100%), five (100%), and three (60%). None of the cases had hypermethylation of RIZ1, p73, VHL, RARbeta, and MGMT. At diagnosis, all patients had concurrent hypermethylation of at least three genes, and five (62%) had concurrent methylation of four or more genes. One patient with plasmacytoma had methylation of E-CAD, ER, and DAPK.
Conclusion: p15, p16, ER, DAPK, and E-CAD (but not RARbeta, p73, VHL, RIZ1, and MGMT) were frequently methylated in MM at both diagnosis and disease progression. Future studies of larger scale are needed to identify the genes responsible for disease progression.
Similar articles
-
Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia.Oncol Rep. 2004 Jul;12(1):97-9. Oncol Rep. 2004. PMID: 15201966
-
Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients.Int J Lab Hematol. 2010 Apr;32(2):142-9. doi: 10.1111/j.1751-553X.2009.01146.x. Epub 2009 Mar 2. Int J Lab Hematol. 2010. PMID: 19302404
-
Aberrant gene promoter methylation in plasma cell dyscrasias.Exp Mol Pathol. 2008 Jun;84(3):256-61. doi: 10.1016/j.yexmp.2008.02.003. Epub 2008 Mar 7. Exp Mol Pathol. 2008. PMID: 18410922
-
Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.Leuk Res. 2006 Nov;30(11):1347-53. doi: 10.1016/j.leukres.2006.03.015. Epub 2006 May 8. Leuk Res. 2006. PMID: 16682076
-
Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach.Clin Lymphoma Myeloma. 2008 Dec;8(6):331-9. doi: 10.3816/CLM.2008.n.048. Clin Lymphoma Myeloma. 2008. PMID: 19064397 Review.
Cited by
-
Targeted therapy for multiple myeloma: an overview on CD138-based strategies.Front Oncol. 2024 Apr 9;14:1370854. doi: 10.3389/fonc.2024.1370854. eCollection 2024. Front Oncol. 2024. PMID: 38655136 Free PMC article. Review.
-
Methylation status of nine tumor suppressor genes in multiple myeloma.Int J Hematol. 2010 Jan;91(1):87-96. doi: 10.1007/s12185-009-0459-2. Int J Hematol. 2010. PMID: 20037750
-
p53 haploinsufficiency and functional abnormalities in multiple myeloma.Leukemia. 2014 Oct;28(10):2066-74. doi: 10.1038/leu.2014.102. Epub 2014 Mar 14. Leukemia. 2014. PMID: 24625551
-
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Oncotarget. 2013 Dec;4(12):2186-207. doi: 10.18632/oncotarget.1497. Oncotarget. 2013. PMID: 24327604 Free PMC article. Review.
-
Clinicopathological significance of the p16 hypermethylation in multiple myeloma, a systematic review and meta-analysis.Oncotarget. 2017 Jun 27;8(47):83270-83279. doi: 10.18632/oncotarget.18742. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous